Merck KGaA completes Millipore acquisition
Merck KGaA, a global pharmaceutical and chemical company, today announced the successful completion of its acquisition of Millipore Corporation, a leading Life Science company based in Massachusetts, USA, for an aggregate purchase price of approximately EUR 5.2 billion.
Merck agreed to acquire Millipore on February 28, 2010 for US$107 in cash per share of Millipore common stock. The closing follows the approval of the acquisition by Millipore’s shareholders and the satisfaction of other customary conditions, including antitrust clearance in the United States and Europe.
Merck will now begin the process of de-listing the shares of Millipore from the New York Stock Exchange and removing the shares from registration with the U.S. Securities and Exchange Commission.
With 10,000 employees in 64 countries, Merck Millipore had pro forma revenues of EUR 2.1 billion for fiscal year 2009. It will be headquartered in Billerica, Massachusetts (USA), and supported by locations throughout the Americas, Europe and Asia-Pacific. The new division will offer a comprehensive range of products, technologies and services for pharma and biotech companies, as well as for academia, to improve laboratory productivity and develop and optimize manufacturing processes.
Source: Merck
